Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 28, 2023 07:00 ET | Source: GeneDx Holdings Corp.

GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium

STAMFORD, Conn., June 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will present new...
December 05, 2022 08:00 ET | Source: Sema4

New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings...
April 28, 2016 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Hold First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, May 5, 2016, at 4:30 p.m. ET

NOVATO, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2016 financial results on Thursday, May 5,...
February 25, 2016 16:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Corp. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Corporate Update

2015 Global Net Revenue for PROCYSBI® of $94.2 Million Reported 2016 Global Net Revenue Guidance of $115 to $125 Million 2016 Anticipated PROCYSBI Growth of 25%-30% Year-Over Year Company to Host...
February 18, 2016 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25, 2016, at 4:30 p.m. ET

NOVATO, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release fourth quarter and full year 2015 financial results on...
January 25, 2016 07:05 ET | Source: Raptor Pharmaceutical Inc

Four New Patents Issued, PROCYSBI® Granted Additional U.S. Orphan Exclusivity

Five Patents for PROCYSBI Now Listed in FDA Orange Book Orphan Drug Exclusivity Extended in Nephropathic Cystinosis Patients 2-6 Years Old NOVATO, Calif., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Raptor...
October 29, 2015 16:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Hold Third Quarter 2015 Financial Results Conference Call and Webcast on Thursday, November 5, 2015, at 4:30 p.m. ET

NOVATO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2015 financial results on Thursday, November 5,...
October 05, 2015 07:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Completes Acquisition of Quinsair(TM)

NOVATO, Calif., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has completed the acquisition of Quinsair™ (levofloxacin inhalation solution)...
September 23, 2015 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Participate in the Leerink Partners 4th Annual Rare Disease Roundtable

NOVATO, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference: Julie Anne Smith,...